Cantor Fitzgerald Brokers Raise Earnings Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Regeneron Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn $37.72 per share for the year, up from their previous forecast of $37.66. Cantor Fitzgerald currently has a “Neutral” rating and a $925.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $38.80 per share.

REGN has been the subject of several other research reports. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. UBS Group increased their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $907.32 on Tuesday. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The company has a 50 day moving average price of $951.41 and a 200 day moving average price of $893.20. The firm has a market capitalization of $99.59 billion, a price-to-earnings ratio of 26.11, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business posted $10.96 earnings per share.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,022 shares of company stock worth $10,552,991. Corporate insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in REGN. Ronald Blue Trust Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 18.8% in the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 12 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 39 shares during the last quarter. Ritholtz Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 18.3% in the third quarter. Ritholtz Wealth Management now owns 510 shares of the biopharmaceutical company’s stock worth $420,000 after buying an additional 79 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 67.1% in the third quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 100 shares during the last quarter. Finally, Park Place Capital Corp lifted its stake in shares of Regeneron Pharmaceuticals by 18.8% in the third quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 15 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.